Press coverage about MEI Pharma (NASDAQ:MEIP) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MEI Pharma earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.6053473179922 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several brokerages recently commented on MEIP. Laidlaw began coverage on MEI Pharma in a research note on Thursday, April 12th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research upgraded MEI Pharma from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Cann restated a “buy” rating on shares of MEI Pharma in a report on Thursday, February 8th. ValuEngine upgraded MEI Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th. Finally, Oppenheimer set a $7.00 target price on MEI Pharma and gave the stock a “buy” rating in a report on Monday, January 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. MEI Pharma currently has a consensus rating of “Buy” and an average target price of $5.63.
MEI Pharma stock traded up $0.01 during mid-day trading on Thursday, hitting $2.14. The stock had a trading volume of 42,049 shares, compared to its average volume of 94,901. The stock has a market cap of $78.18, a price-to-earnings ratio of 30.57 and a beta of 1.91. MEI Pharma has a 12 month low of $1.52 and a 12 month high of $3.26.
MEI Pharma (NASDAQ:MEIP) last posted its quarterly earnings results on Thursday, February 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.10. The business had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $1.00 million. MEI Pharma had a negative return on equity of 42.23% and a negative net margin of 354.10%. research analysts predict that MEI Pharma will post -0.95 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-mei-pharma-meip-stock-price.html.
About MEI Pharma
MEI Pharma, Inc, an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.